AIM
ENTA icon

Acrospire Investment Management’s Enanta Pharmaceuticals ENTA Stock Holding History

Acrospire Investment Management’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-3,200
Closed -$107K – 2279
2016
Q4 		$107K Buy
3,200
+1,100
+52% +$31.5K 0.04% 884
2016
Q3 		$56K Buy
2,100
+1,100
+110% +$25.5K 0.04% 979
2016
Q2 		$22K Sell
1,000
-700
-41% -$18.3K 0.02% 1491
2016
Q1 		$50K Buy
+1,700
New +$47.3K 0.03% 945

Other funds holding ENTA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
MCM
Matarin Capital Management New York $409M AUM 33.03% 1-Year Est. Return

Acrospire Investment Management's ENTA Position: Q1 2017 in Review

Acrospire Investment Management sold out of Enanta Pharmaceuticals (ENTA) in Q1 2017, closing a stake of 3,200 shares — an estimated $107K sold.

Acrospire Investment Management first reported a position in ENTA in Q1 2016 and held it in 4 quarters. The position peaked at $107K in Q4 2016. 126 funds tracked by Wall St. Rank hold ENTA as of Q1 2017.

  • Acrospire Investment Management reported no remaining Enanta Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
  • Acrospire Investment Management sold 3,200 Enanta Pharmaceuticals shares in Q1 2017, an estimated $107K.
  • Acrospire Investment Management first reported a position in Enanta Pharmaceuticals in Q1 2016 and held it in 4 quarters.
  • Acrospire Investment Management's Enanta Pharmaceuticals position peaked at $107K in Q4 2016.
  • 126 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q1 2017.

Based on Acrospire Investment Management's 13F filing for Q1 2017, filed 4 May 2017.